Abrysvo, which is now the first maternal RSV vaccine to be prequalified by the organisation, aims to prevent RSV-associated ...
On 12 March 2025, the World Health Organization (WHO) prequalified the first maternal respiratory syncytial virus (RSV) vaccine to protect infants ...
Vietnam Investment Review on MSN3d
AIM Vaccine's mRNA Shingles Vaccine Approved by the US FDA to Begin Clinical Trials, AI-Enabled mRNA Major Vaccine Product Development AcceleratesRecently, AIM announced a comprehensive deployment to integrate the DeepSeek large model, particularly in vaccine development ...
CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products ... authorization of our RSV vaccine is an important ...
Moderna (MRNA) announced that the Medicines and Healthcare products ... active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in adults ...
"The MHRA's authorization of our RSV vaccine is an important milestone for Moderna's efforts toward respiratory disease preparedness," said Stéphane Bancel, Chief Executive Officer of Moderna.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback